Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05518539 · ClinicalTrials.gov registry record

Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens

A clinical trial of Cataract, sponsored by Newsom Eye & Laser Center.

Completed
Registry status
30
Enrollment target
1
Study location

NCT05518539 is a study of Cataract that has completed, run by Newsom Eye & Laser Center. The registered enrollment target is 30 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05518539, a study of Cataract, has completed, sponsored by Newsom Eye & Laser Center.

COMPLETED
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

To evaluate visual outcomes and quality of vision following bilateral implantation of the Clareon PanOptix intraocular lens (IOL) targeted for emmetropia.

Conditions Studied

Interventions

  • DEVICE The Clareon™ PanOptix™ Trifocal (toric and non-toric models)

Study Locations (1)

Florida

  • Newsom Eye & Laser Center - Sebring

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-09-08
Est. Completion 2024-06-14

Sponsor

Newsom Eye & Laser Center

2 total trials

What the Registry Record Tells You About NCT05518539

The ClinicalTrials.gov registry entry for NCT05518539 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (87% lower). The listed sponsor is Newsom Eye & Laser Center, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which The Clareon™ PanOptix™ Trifocal (toric and non-toric models) is the first listed.

NCT05518539 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05518539 about?

NCT05518539 is a clinical study titled "Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens". To evaluate visual outcomes and quality of vision following bilateral implantation of the Clareon PanOptix intraocular lens (IOL) targeted for emmetropia.

What is the current status of trial NCT05518539?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2022-09-08. Estimated completion is 2024-06-14.

What conditions does trial NCT05518539 study?

This clinical trial studies the following conditions: Cataract.

What interventions are being tested in trial NCT05518539?

The interventions under investigation include: The Clareon™ PanOptix™ Trifocal (toric and non-toric models) (DEVICE).

Who is sponsoring clinical trial NCT05518539?

This trial is sponsored by Newsom Eye & Laser Center, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05518539 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.